Johnson & Johnson’s Launch of Invokana Bodes Well for SGLT-2 Class
Compiled by Sam Fazeli, Bloomberg Industries and Elizabeth Krutoholow
Johnson & Johnson’s newly launched diabetes drug Invokana appears to have fairly strong uptake, according to data from inThought Research. This may bode well for other agents in the new SGLT-2 class, said Christopher Martin, Senior Principal, Symphony Health Solutions in a webcast with Bloomberg Industries’ Sam Fazeli.
Fixed dose combinations with other drugs for diabetes like DPP4 inhibitors will be critical for growth of this class, the analysts said.